Scarica l'app Stockscreener
2.59
1.57%
0.04
Dopo l'orario di chiusura:
2.61
0.02
+0.77%
Kiora Pharmaceuticals Inc Borsa (KPRX) Ultime notizie
Perceptive Advisors LLC Acquires New Position in Kiora Pharmaceuticals Inc (KPRX) - GuruFocus
ADAR1 group discloses 9.9% Kiora Pharmaceuticals (KPRX) stake via shares and warrants - Stock Titan
Nantahala Capital discloses 9.99% Kiora Pharmaceuticals (KPRX) stake via 13G/A filing - Stock Titan
Kiora Pharmaceuticals (KPRX) reports 9.99% stake held by Perceptive group - Stock Titan
Form 8K Kiora Pharmaceuticals Inc For: 7 August By Investing.com - Investing.com Nigeria
Kiora Pharmaceuticals advances retinal disease trials, secures $24M funding, expects data in 2027 - Pluang
Kiora Pharmaceuticals, Inc. reports results for the quarter ended June 30Earnings Summary - TradingView
Kiora Pharmaceuticals Reports Second Quarter 2026 Financial Results and Provides Corporate Update - TMX Newsfile
Kiora Starts Enrollment in 100-Microgram Retinitis Pigmentosa Cohort - Stock Titan
Kiora Pharmaceuticals (KPRX) Gains 2.83% as Shares Approach $2.67 ResistanceGap and Reverse - dars.gov.et
Kiora Pharmaceuticals, Inc. expected to post a loss of 62 cents a shareEarnings Preview - TradingView
Kiora Pharmaceuticals Inc (KPRX) Dividends & Stock Splits: Historical Payouts and Event Timeline - TradingKey
Kiora Pharmaceuticals Market Sentiment - Benzinga España
Kiora Pharmaceuticals Inc (KPRX) Shareholder Structure: Major Shareholders & Institutional Holdings - TradingKey
KPRX|Kiora Pharmaceuticals Inc|Price:2.530|Chg%:-0.020 - TradingKey
TradingKey - TradingKey
Kiora Pharmaceuticals Inc (KPRX) Revenue Breakdown: Business Segments, Regional Revenue & Profit Contribution - TradingKey
Kiora Pharmaceuticals Q1 2026 Earnings: EPS Beat as Pre‑Revenue Biotech Narrows Loss ExpectationsPerformance Review - dars.gov.et
Kiora Pharmaceuticals (KPRX) Edges Higher as Shares Test Key ResistanceKAMA Signal - dars.gov.et
Kiora Pharmaceuticals, Inc. Revenue Breakdown – NASDAQ:KPRX - TradingView
Kiora Pharmaceuticals Inc (KPRX) Risk Assessment: Volatility, Financial Risk & Investment Risk - TradingKey
Kiora Pharmaceuticals (KPRX) Slips 2.7% as Biotech Sector Faces Renewed PressureVolatility Breakout Picks - dars.gov.et
Price to sales forward of Kiora Pharmaceuticals, Inc. – FWB:7EY - TradingView
Enterprise value to revenue forward of Kiora Pharmaceuticals, Inc. – FWB:7EY - TradingView
Enterprise value to revenue forward of Kiora Pharmaceuticals, Inc. – LS:A40EG5 - TradingView
Kiora Pharmaceuticals Inc. (KPRX) Stock Price | Live Quotes & Charts | NASDAQ - timothysykes.com
Enterprise value to revenue forward of Kiora Pharmaceuticals, Inc. – GETTEX:7EY - TradingView
Price to earnings forward of Kiora Pharmaceuticals, Inc. – NASDAQ:KPRX - TradingView
Price to book forward of Kiora Pharmaceuticals, Inc. – NASDAQ:KPRX - TradingView
Enterprise value to EBITDA forward of Kiora Pharmaceuticals, Inc. – NASDAQ:KPRX - TradingView
KPRXKiora Pharmaceuticals Inc Latest SEC Filings - Finviz
Form 4 Kiora Pharmaceuticals Inc For: 2 July By Investing.com - Investing.com India
Kiora (NASDAQ: KPRX) CFO uses 911 shares to cover tax obligations - Stock Titan
[Form 4] KIORA PHARMACEUTICALS INC Insider Trading Activity - Stock Titan
Kiora Pharmaceuticals (KPRX) Holds Steady Near Support as Biotech Sector WatchesRelative Volume - dars.gov.et
Kiora Pharmaceuticals to Participate in Piper Sandler Virtual Ophthalmology Symposium - TMX Newsfile
Kiora Pharmaceuticals Inc Warrant 2022-27.09.27 on Kiora Pharma A Financial Disclosures & SEC Filings - TradingView
Kiora Pharmaceuticals (KPRX) Slides Marginally as Biotech Sector Remains CautiousMonthly Profile - po-news-eg.net
Kiora Pharmaceuticals, Inc. Actuals & Estimates (NASDAQ:KPRX) - TradingView
KPRX Forecast — Price Target — Prediction for 2027 - TradingView
7EY Forecast — Price Target — Prediction for 2027 - TradingView
Why Did KPRX Stock Surge 17% Pre-Market Today? - Stocktwits
Kiora Pharmaceuticals Inc (KPRX) Institutional Confidence - TradingKey
Kiora Pharmaceuticals Inc (KPRX) Technical Analysis: Support, Resistance, Indicators & Moving Averages - TradingKey
Analysts Are Bullish on Top Healthcare Stocks: Ascentage Pharma Group International (HK:6855), Kiora Pharmaceuticals (KPRX) - The Globe and Mail
Kiora Pharmaceuticals (KPRX) Slips Slightly as Stock Hovers Near Key Support ZoneDouble Top - dars.gov.et
KPRX SEC FilingsKIORA PHARMACEUTICALS INC 10-K, 10-Q, 8-K Forms - Stock Titan
Kiora Pharmaceuticals (KPRX) FDA Approvals, PDUFA Dates & Drug Alerts 2026 - MarketBeat
Kiora Pharmaceuticals’ KIO-300 Shows Significant Seizure Suppression in Preclinical Epilepsy Model, Revealing Potential Beyond Ophthalmology 1 – Minichart - Minichart
Kiora Pharmaceuticals Reports its Ion Channel Modulator, KIO-300, Suppressed Seizure Activity in Preclinical Epilepsy Model - TMX Newsfile
Kiora Pharmaceuticals (NASDAQ: KPRX) reports KIO-300 epilepsy model data - Stock Titan
Kiora Pharmaceuticals Inc (KPRX) Valuation: PE, PB & Fair Value Analysis - TradingKey
Kiora's KIO-300 cut epileptiform activity in epilepsy model - Stock Titan
Kiora Pharmaceuticals Inc (KPRX) Earnings Forecast: Future EPS & Revenue Growth Estimates - TradingKey
Kiora Pharmaceuticals Inc (KPRX) Financial Health: Profitability & Balance Sheet Analysis - TradingKey
Kiora Pharmaceuticals (NASDAQ: KPRX) director receives stock options for 25,000 shares - Stock Titan
Kiora Pharmaceuticals (KPRX) director receives 25,000 stock options grant - Stock Titan
Director at Kiora (KPRX) receives 25,000 stock options at $2.63 strike - Stock Titan
Kiora Pharmaceuticals (KPRX) director granted 25,000 stock options at $2.63 strike - Stock Titan
Kiora Pharmaceuticals (KPRX) director awarded 25,000 stock options - Stock Titan
Kiora (KPRX) director Praveen Tyle receives stock options for 40,000 shares - Stock Titan
1.80%
1.77%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):